The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era

Okura, Miyuki; Ida, Naoko; Yamauchi, Takahiro

doi:10.1007/s12032-020-01423-4

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This immunohistochemical staining pattern was in concordance with the commonly observed immunophenotype of PCM, characterized by the absence of pan‐B marker CD20 and abnormal gain of CD56 15,16 . While normal plasma cells do not express CD56, the neoplastic plasma cells of PCM are generally positive for CD56; the prognostic implications of CD56 positivity are still being evaluated 17 …”

Section: Discussionsupporting

confidence: 82%

“…15,16 While normal plasma cells do not express CD56, the neoplastic plasma cells of PCM are generally positive for CD56; the prognostic implications of CD56 positivity are still being evaluated. 17 Despite its common utility as a pan-leukocyte marker, CD45 is frequently negative in PCNs, particularly in advanced disease. 15 The only immunohistochemical staining exception in our case was the aberrant CD4 positivity, which is a well-established T-cell lineage marker.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous involvement by plasma cell myeloma with aberrant CD4 expression

Panse

Singh³

et al. 2021

J Cutan Pathol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Cutaneous involvement by plasma cell myeloma with aberrant CD4 expression

Panse

Singh³

et al. 2021

J Cutan Pathol

View full text Add to dashboard Cite

“…Therefore, we used survival analysis to compare the CD56 − CD117 − with the other three groups, and we discovered that the CD56 − CD117 − group had a significantly worse OS. According to prior research, the dual negativity of CD56 and CD117 indicates a poor prognosis [ 7 , 18 , 25 ]. In this study, CD56 − was identified as an independent prognostic factor for a poor outcome.…”

Section: Discussionmentioning

confidence: 99%

Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma

Zheng

Zhu

et al. 2022

JCM

View full text Add to dashboard Cite

The prognostic value of CD56 and CD117 expression on myeloma cells is controversial. This study aims to analyze the correlation of CD56 and CD117 expression with cytogenetic abnormalities and survival. A total of 128 patients with newly diagnosed multiple myeloma (NDMM) were recruited in this single-center retrospective study. Flow cytometry and FISH tests of marrow cells were performed for all of the subjects. The statistical methods included a chi-squared test, univariate and multivariate COX regressions, and a Kaplan-Meier survival curve analysis. Regarding the cytogenetics, the incidence of IgH/FGFR3 translocation was more frequent in patients with a negative CD56 (p = 0.003). CD56 negativity was an independent adverse factor associated with a poor prognosis (p = 0.019) and indicated a shorter overall survival (OS) (p = 0.021). Patients with dual negative CD56 and CD117 trended toward a poorer OS (CD56−CD117− vs. CD56+CD117−, p = 0.011; CD56−CD117− vs. CD56+CD117+, p = 0.013). In conclusion, CD56 is a prognostic marker that independently affects OS and is associated with adverse cytogenetic abnormalities. Patients with a dual negativity of CD56 and CD117 have a worse clinical outcome.

show abstract

“…Others have shown that CD56 absence may be associated with extramedullary involvement, plasma-blastic morphology, a plasma cell leukemia (PCL) state, non-hyper-diploid chromosomal abnormalities, and eventually worse PFS [ 65 , 77 , 80 , 81 ]. Okura et al also reported on worse OS for CD56-negative MM [ 82 ]. In conclusion, CD56 may indeed be associated with prognosis and remains as one of the leading MM markers [ 83 ].…”

Section: Introductionmentioning

confidence: 99%

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

Lebel

Nachmias

Pick

et al. 2022

JCM

View full text Add to dashboard Cite

Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to the bone marrow matrix and stromal cells, while others are involved in intercellular interactions that result in differentiation of B-cells to plasma cells (PC). These interactions are also involved in malignant transformation of the normal PC to MM PC as well as disease progression. Here, we review selected surface antigens that are commonly used in the flow cytometry analysis of MM for identification of plasma cells (PC) and the discrimination between normal and malignant PC as well as prognostication. These include the markers: CD38, CD138, CD45, CD19, CD117, CD56, CD81, CD27, and CD28. Furthermore, we will discuss the novel marker CD24 and its involvement in MM. The bioactivity of each antigen is reviewed, as well as its expression on normal vs. malignant PC, prognostic implications, and therapeutic utility. Understanding the role of these specific surface antigens, as well as complex co-expressions of combinations of antigens, may allow for a more personalized prognostic monitoring and treatment of MM patients.

show abstract

The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era

Cited by 8 publications

References 26 publications

Cutaneous involvement by plasma cell myeloma with aberrant CD4 expression

Cutaneous involvement by plasma cell myeloma with aberrant CD4 expression

Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

Contact Info

Product

Resources

About